1. Home
  2. CLPT vs LYEL Comparison

CLPT vs LYEL Comparison

Compare CLPT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ClearPoint Neuro Inc.

CLPT

ClearPoint Neuro Inc.

HOLD

Current Price

$10.50

Market Cap

494.6M

Sector

Health Care

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.70

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPT
LYEL
Founded
1998
2018
Country
United States
United States
Employees
N/A
161
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
494.6M
556.1M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
CLPT
LYEL
Price
$10.50
$23.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$20.00
$30.60
AVG Volume (30 Days)
632.0K
74.3K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$36,971,000.00
$36,000.00
Revenue This Year
$45.67
N/A
Revenue Next Year
$19.51
$16,285.34
P/E Ratio
N/A
N/A
Revenue Growth
17.78
N/A
52 Week Low
$8.27
$0.39
52 Week High
$30.10
$45.00

Technical Indicators

Market Signals
Indicator
CLPT
LYEL
Relative Strength Index (RSI) 54.90 55.08
Support Level $10.02 $21.27
Resistance Level $11.74 $27.30
Average True Range (ATR) 0.54 1.71
MACD 0.29 0.43
Stochastic Oscillator 90.32 74.68

Price Performance

Historical Comparison
CLPT
LYEL

About CLPT ClearPoint Neuro Inc.

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: